Connect with us

Technology

Dolby Laboratories Reports Third Quarter 2026 Financial Results

Published

on

SAN FRANCISCO, July 30, 2026 /PRNewswire/ — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the third quarter of fiscal 2026.

“We continue to execute against our full-year objectives, and we are building momentum across several of our key growth areas,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “We are expanding our total addressable market and creating new opportunities with content partners through the Video Distribution Program and Dolby OptiView, and we continue to bring Dolby Atmos and Dolby Vision to more experiences from live sports, to music in the car, to user-generated content on mobile devices and more.”

Third Quarter Fiscal 2026 Financial Highlights

Total revenue was $305 million, compared to $316 million for the third quarter of fiscal 2025.GAAP net income was $29 million or $0.30 per diluted share, compared to GAAP net income of $46 million or $0.48 per diluted share for the third quarter of fiscal 2025. On a non-GAAP basis, third quarter net income was $65 million or $0.69 per diluted share, compared to $76 million or $0.78 per diluted share for the third quarter of fiscal 2025.Dolby repurchased 1.2 million shares of its common stock for approximately $65 million.

A complete listing of Dolby’s non-GAAP measures is described and reconciled to the corresponding GAAP measures at the end of this release. 

Recent Business Highlights

The 2026 FIFA World Cup was shown in Dolby Atmos and/or Dolby Vision across broadcast, streaming, and pay TV, including Peacock and Comcast in the U.S., Bell TV in Canada, and TV GLOBAL in Brazil.On TVs, Dolby Vision 2 is now in market with some Hisense TVs, and by the end of this calendar year, TCL and Philips will also be shipping TVs with Dolby Vision 2. RayNeo, the leading provider of augmented reality glasses, launched the RayNeo GT Max, the first AR smart glasses supporting Dolby Vision.Insta360, a leader in the action and panoramic cameras segments, launched the Luna Ultra, which supports Dolby Vision capture.Google announced support for Dolby Atmos through Android Auto with partners including BMW, Genesis, Mahindra, Mercedes, Renault, and Skoda.Roberts Communications Network, the largest horse racing streaming provider in the U.S., is using Dolby OptiView for ultra-low latency video streaming for horse racing.Access Advance announced that Meta Platforms, Inc., one of the world’s largest distributors of video content, joined the VDP program as a licensee.

Dividend

Today, Dolby announced a cash dividend of $0.36 per share of Class A and Class B common stock, payable on August 19, 2026, to stockholders of record as of the close of business on August 11, 2026.

Stock Repurchase Program

Today, Dolby also announced that its Board of Directors has approved increasing the size of its stock repurchase program by $350 million, bringing the amount available for future repurchases of its Class A Common Stock to approximately $427 million. Stock repurchases under this program may be made through open market transactions, negotiated purchases, or otherwise, at times and in amounts that the company considers appropriate.

Financial Outlook

Dolby’s financial outlook relies, in part, on estimates of royalty-based revenue that take into consideration various factors that are subject to uncertainty, including consumer demand for electronic products. In addition, actual results could differ materially from the estimates Dolby is providing herein due in part to uncertainty resulting from the macroeconomic effect of certain conditions, including developments concerning trade restrictions and changes in trade or diplomatic relationships, supply chain constraints, international conflicts, geopolitical instability, and fluctuations in inflation and interest rates. The uncertainty resulting from these factors has greatly reduced visibility into Dolby’s future outlook. To the extent possible, the estimates Dolby is providing for future periods reflect certain assumptions about the potential impact of certain of these items, based upon a consideration of currently available external and internal data and information. These assumptions are subject to risks and uncertainties. For more information, see “Forward-Looking Statements” in this press release for a description of certain risks that Dolby faces, and the section captioned “Risk Factors” in its Quarterly Report on Form 10-Q for the third quarter of fiscal 2026, to be filed on or around the date hereof.

Dolby is providing the following estimates for its fourth quarter of fiscal 2026:

Total revenue is expected to range from $362 million to $392 million.Licensing revenue is expected to range from $335 million to $365 million. Gross margins are anticipated to be approximately 88% on a GAAP basis and approximately 90% on a non-GAAP basis.Operating expenses are anticipated to range from $227 million to $237 million on a GAAP basis and from $195 million to $205 million on a non-GAAP basis.Effective tax rate is anticipated to be around 23% on a GAAP basis and around 21% on a non-GAAP basis.Diluted earnings per share is anticipated to range from $0.78 to $0.93 on a GAAP basis and from $1.13 to $1.28 on a non-GAAP basis.

Dolby is providing the following estimates for the full year of fiscal 2026:

Total revenue is expected to range from $1.41 billion to $1.44 billion.Licensing revenue is expected to range from $1.31 billion to $1.34 billion. Gross margins are anticipated to be approximately 88% on a GAAP basis and approximately 90% on a non-GAAP basis.Operating expenses are anticipated to range from $937 million to $947 million on a GAAP basis and from $785 million to $795 million on a non-GAAP basis.Dolby expects operating margins to be approximately 21% on a GAAP basis and to be approximately 34% on a non-GAAP basis.Effective tax rate is anticipated to be around 24% on a GAAP basis and around 21% on a non-GAAP basis.Diluted earnings per share is anticipated to range from $2.62 to $2.77 on a GAAP basis and from $4.25 to $4.40 on a non-GAAP basis.

Conference Call Information

Members of Dolby management will lead a conference call open to all interested parties to discuss third quarter fiscal 2026 financial results for Dolby Laboratories at 2:00 p.m. PT (5:00 p.m. ET) on Thursday, July 30, 2026.

The conference call can be accessed by registering online at Dolby Laboratories Q3 Fiscal Year 2026 Financial Results, at which time registrants will receive dial-in information as well as a conference ID.

A live audio webcast of the conference call will be available at http://investor.dolby.com where it will be archived for one year.

Non-GAAP Financial Information

To supplement Dolby’s financial statements presented on a GAAP basis, Dolby management uses, and Dolby provides to investors, certain non-GAAP financial measures as an additional tool to evaluate Dolby’s operating results in a manner that focuses on what Dolby’s management believes to be its ongoing business operations and performance. We believe these non-GAAP financial measures are also helpful to investors in enabling comparability of operating performance between periods and among peer companies. Additionally, Dolby’s management regularly uses our supplemental non-GAAP financial measures to make operating decisions, for planning and forecasting purposes and determining bonus payouts. Specifically, Dolby excludes the following as adjustments from one or more of its non-GAAP financial measures:

Stock-based compensation expense: Stock-based compensation, unlike cash-based compensation, utilizes subjective assumptions in the methodologies used to value the various stock-based award types that Dolby grants. These assumptions may differ from those used by other companies. To facilitate more meaningful comparisons between its underlying operating results and those of other companies, Dolby excludes stock-based compensation expense.

Amortization of acquisition-related intangibles: Dolby amortizes intangible assets acquired in connection with business combinations. These intangible assets consist of patents and technology, customer relationships, and other intangibles. Dolby records amortization charges relating to these intangible assets in its GAAP financial statements, and Dolby views these charges as items arising from pre-acquisition activities that are determined by the timing and valuation of its acquisitions. As these amortization charges do not directly correlate to its operations during any particular period, Dolby excludes these charges to facilitate an evaluation of its current operating performance and comparisons to its past operating results. In addition, while amortization expense of acquisition-related intangible assets is excluded from Non-GAAP Net Income, the revenue generated from those assets is not excluded.

Restructuring charges or credits: Restructuring charges are costs associated with restructuring plans and primarily relate to costs associated with exit or disposal activities, employee severance benefits, and asset impairments. Dolby excludes restructuring costs, including any adjustments to charges recorded in prior periods (which may be credits), as Dolby believes that these costs are not representative of its normal operating activities and therefore, excluding these amounts enables a more effective comparison of its past operating performance and to that of other companies.

Income tax adjustments: The income tax effects of the aforementioned non-GAAP adjustments do not directly correlate to its operating performance so Dolby believes that excluding such income tax effects provides a more meaningful view of its underlying operating results to management and investors.

Using the aforementioned adjustments, Dolby provides various non-GAAP financial measures including, but not limited to: non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating margin, and non-GAAP effective tax rate. Dolby’s management believes it is useful for itself and investors to review both GAAP and non-GAAP measures to assess the performance of Dolby’s business, including

as a means to evaluate period-to-period comparisons. Dolby’s management does not itself, nor does it suggest that investors should, consider non-GAAP financial measures in isolation from, superior to, or as a substitute for, financial information prepared in accordance with GAAP. Whenever Dolby uses non-GAAP financial measures, it provides a reconciliation of the non-GAAP financial measures to the most closely applicable GAAP financial measures. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as detailed above and below. Investors are also encouraged to review Dolby’s GAAP financial statements as reported in its US Securities and Exchange Commission (SEC) filings. A reconciliation between GAAP and non-GAAP financial measures is provided at the end of this press release and on the Dolby investor relations website, http://investor.dolby.com.

Forward-Looking Statements

Certain statements in this press release and in our earnings calls, including, but not limited to, expected financial results for the fourth quarter of fiscal 2026 and full year fiscal 2026, Dolby’s ability to expand existing business, navigate challenging periods, pursue its long-term growth opportunities, and advance its other long-term objectives are “forward-looking statements” that inherently involve substantial risks and uncertainties. These forward-looking statements are based on management’s current expectations, and as a result of certain risks and uncertainties, actual results may differ materially from those provided. The following important factors, without limitation, could cause actual results to differ materially from those in the forward-looking statements: the potential impacts of economic conditions on Dolby’s business operations, financial results, and financial position (including the impact to Dolby partners and disruption of the supply chain and delays in shipments of consumer products; the level at which Dolby technologies are incorporated into products and the consumer demand for such products; delays in the development and release of new products or services that contain Dolby technologies; delays in royalty reporting or delinquent payment by partners or licensees; lengthening sales cycles; the impact to the overall cinema market including adverse impact to Dolby’s revenue recognized on box-office sales and demand for cinema products and services; and macroeconomic conditions that affect discretionary spending and access to products that contain Dolby technologies); risks associated with geopolitical issues and international conflicts; risks associated with trends in the markets in which Dolby operates, including the broadcast, mobile, consumer electronics, PC, and other markets; the loss of, or reduction in sales by, a key customer, partner, or licensee; pricing pressures; risks relating to changing trends in the way that content is distributed and consumed; risks relating to conducting business internationally, including trade restrictions and changes in diplomatic or trade relationships; risks relating to maintaining patent coverage; the timing of Dolby’s receipt of royalty reports and payments from its licensees, including recoveries; changes in tax regulations; timing of revenue recognition under licensing agreements and other contractual arrangements; Dolby’s ability to develop, maintain, and strengthen relationships with industry participants; Dolby’s ability to develop and deliver innovative products and technologies in response to new and growing markets; competitive risks; risks associated with conducting business in countries that have historically limited recognition and enforcement of intellectual property and contractual rights; risks associated with the health of the motion picture and cinema industries generally; Dolby’s ability to increase its revenue streams and to expand its business generally, and to continue to expand its business beyond its current technology offerings; risks associated with acquiring and successfully integrating businesses or technologies; and other risks detailed in Dolby’s SEC filings and reports, including the risks identified under the section captioned “Risk Factors” in its Quarterly Report on Form 10-Q filed on or around the date hereof. Dolby may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements. Forward-looking statements are based upon information available to us as of the date of such statements, and while Dolby believes such information forms a reasonable basis for such statements, such information may be limited or incomplete. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Except as required by law, Dolby disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

About Dolby

Dolby Laboratories (NYSE: DLB) is a world leader in immersive entertainment. From movies and TV, to music, sports, gaming, and beyond, Dolby transforms the science of sight and sound into spectacular experiences for billions of people worldwide across all their favorite devices. We partner with artists, storytellers, and the brands you love to transform entertainment and digital experiences through groundbreaking innovations like Dolby Atmos, Dolby Vision, Dolby Cinema, and Dolby OptiView.

Dolby, Dolby Atmos, Dolby Vision, Dolby Cinema, Dolby OptiView, and the double-D symbol are among the registered and unregistered trademarks of Dolby Laboratories in the United States and/or other countries. Other trademarks remain the property of their respective owners.

DOLBY LABORATORIES, INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts; unaudited)

Fiscal Quarter Ended

Fiscal Year-To-Date Ended

June 26,
2026

June 27,
2025

June 26,
2026

June 27,
2025

Revenue:

  Licensing

$          282,351

$          289,905

$          974,367

$          966,390

  Products and services

22,644

25,641

72,964

75,716

Total revenue

304,995

315,546

1,047,331

1,042,106

Cost of revenue:

  Cost of licensing

22,718

21,713

67,523

62,508

  Cost of products and services

17,601

22,289

60,735

58,105

Total cost of revenue

40,319

44,002

128,258

120,613

Gross profit

264,676

271,544

919,073

921,493

Operating expenses:

  Research and development

65,749

65,982

198,477

194,327

  Sales and marketing

85,071

86,163

272,786

270,191

  General and administrative

75,585

72,307

221,783

212,814

  Restructuring charges/(credits)

3,955

(547)

16,605

8,879

Total operating expenses

230,360

223,905

709,651

686,211

Operating income

34,316

47,639

209,422

235,282

Other income/(expense):

  Interest income/(expense), net

3,453

4,111

12,595

10,316

  Other income, net

6,033

3,766

13,086

16,219

Total other income

9,486

7,877

25,681

26,535

Income before income taxes

43,802

55,516

235,103

261,817

 Provision for income taxes

(14,588)

(8,974)

(56,754)

(54,979)

Net income including noncontrolling interest

29,214

46,542

178,349

206,838

 Less: net income attributable to noncontrolling interest

(612)

(471)

(1,505)

(1,152)

Net income attributable to Dolby Laboratories, Inc.

$           28,602

$           46,071

$          176,844

$          205,686

Net income per share:

Basic

$              0.30

$              0.48

$              1.86

$              2.14

Diluted

$              0.30

$              0.48

$              1.84

$              2.11

Weighted-average shares outstanding:

Basic

94,242

95,897

94,975

95,947

Diluted

94,518

96,900

95,859

97,537

 

DOLBY LABORATORIES, INC.
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands; unaudited)

June 26,
2026

September 26,
2025

ASSETS

Current assets:

 Cash and cash equivalents

$          669,394

$          701,893

 Restricted cash

69,492

91,468

 Short-term investments

652

703

 Accounts receivable, net

285,148

331,096

 Contract assets, net

206,881

180,804

 Inventories, net

30,768

30,424

 Prepaid expenses and other current assets

63,706

51,873

Total current assets

1,326,041

1,388,261

 Long-term investments

86,437

80,205

 Property, plant, and equipment, net

459,115

470,608

 Operating lease right-of-use assets

42,401

33,204

 Goodwill and intangible assets, net

910,777

926,957

 Deferred taxes

213,171

214,361

 Other non-current assets

118,660

114,164

Total assets

$        3,156,602

$        3,227,760

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

 Accounts payable

$           12,470

$           17,840

 Accrued liabilities

360,407

369,256

 Income taxes payable

8,928

 Contract liabilities

33,593

31,382

 Operating lease liabilities

9,859

10,384

Total current liabilities

416,329

437,790

 Non-current contract liabilities

23,463

29,687

 Non-current operating lease liabilities

37,591

28,494

 Other non-current liabilities

86,504

99,843

Total liabilities

563,887

595,814

Stockholders’ equity:

 Class A common stock

52

54

 Class B common stock

40

40

 Retained earnings

2,598,923

2,634,980

 Accumulated other comprehensive loss

(15,468)

(12,517)

Total stockholders’ equity – Dolby Laboratories, Inc.

2,583,547

2,622,557

 Noncontrolling interest

9,168

9,389

Total stockholders’ equity

2,592,715

2,631,946

Total liabilities and stockholders’ equity

$        3,156,602

$        3,227,760

 

DOLBY LABORATORIES, INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands; unaudited)

Fiscal Year-To-Date Ended

June 26,
2026

June 27,
2025

Operating activities:

Net income including noncontrolling interest

$          178,349

$          206,838

Adjustments to reconcile net income to net cash provided by operating activities:

  Depreciation and amortization

70,842

65,829

  Stock-based compensation

98,883

97,462

  Amortization of operating lease right-of-use assets

7,889

8,193

  Provision for credit losses

4,244

2,582

  Deferred income taxes

1,542

(9,146)

  Share of net income of equity method investees, net of cash distributions

(7,602)

1,845

  Other non-cash items affecting net income

(1,289)

(429)

  Changes in operating assets and liabilities:

 Accounts receivable, net

1,489

15,234

 Contract assets, net

(28,442)

(6,902)

 Inventories

6,512

4,020

 Operating lease right-of-use assets

(17,547)

(1,717)

 Prepaid expenses and other assets

(31,999)

28,003

 Accounts payable and accrued liabilities

35,611

(48,979)

 Income taxes, net

(2,771)

1,895

 Contract liabilities

1,620

(1,061)

 Operating lease liabilities

9,036

(8,237)

 Other non-current liabilities

(11,600)

(6,063)

Net cash provided by operating activities

314,767

349,367

Investing activities:

 Proceeds from sales of marketable securities

15,911

 Proceeds from sale of assets held for sale

16,881

 Purchases of property, plant, and equipment

(28,681)

(20,104)

 Business combinations, net of cash and restricted cash acquired, and other related payments

(1,362)

 Purchases of intangible assets

(42,575)

 Proceeds from sale of intangible assets

16,623

Net cash provided by/(used in) investing activities

(54,633)

11,326

Financing activities:

 Proceeds from issuance of common stock

24,685

38,681

 Repurchase of common stock

(200,001)

(89,990)

 Payment of excise tax on repurchase of common stock

(261)

 Payment of cash dividend

(102,659)

(95,010)

 Distributions to noncontrolling interest

(1,640)

(1,449)

 Shares repurchased for tax withholdings on vesting of restricted stock

(33,113)

(35,154)

Net cash used in financing activities

(312,728)

(183,183)

 Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash

(1,881)

1,302

Net increase/(decrease) in cash, cash equivalents, and restricted cash

(54,475)

178,812

Cash, cash equivalents, and restricted cash at beginning of period

793,361

577,752

Cash, cash equivalents, and restricted cash at end of period

$          738,886

$          756,564

 

Licensing Revenue by Market
(unaudited)

The following table presents the composition of our licensing revenue and percentage of total licensing revenue for all periods presented (in thousands,
except percentage amounts):

Fiscal Quarter Ended

Fiscal Year-To-Date Ended

Market

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Broadcast

$  106,579

38 %

$  111,286

38 %

$  326,041

33 %

$  321,297

33 %

Mobile

51,010

18 %

56,295

19 %

220,199

23 %

217,942

23 %

CE

31,506

11 %

28,071

10 %

118,057

12 %

115,668

12 %

PC

28,343

10 %

33,589

12 %

116,523

12 %

123,247

13 %

Other

64,913

23 %

60,664

21 %

193,547

20 %

188,236

19 %

Total licensing revenue

$  282,351

100 %

$  289,905

100 %

$  974,367

100 %

$  966,390

100 %

GAAP to Non-GAAP Reconciliations

(unaudited)

The following tables present Dolby’s GAAP financial measures reconciled to the non-GAAP financial measures included in this release for the third
 quarters of fiscal 2026 and fiscal 2025:

Net income:

Fiscal Quarter Ended

(in thousands)

June 26,
2026

June 27,
2025

GAAP net income attributable to Dolby Laboratories, Inc.

$         28,602

$         46,071

Stock-based compensation (1)

30,964

30,728

Amortization of acquisition-related intangibles (2)

9,705

10,016

Restructuring charges/(credits)

3,955

(547)

Income tax adjustments

(8,077)

(10,606)

Non-GAAP net income attributable to Dolby Laboratories, Inc.

$         65,149

$         75,662

(1) Stock-based compensation included in above line items:

  Cost of products and services

$            440

$            420

  Research and development

9,695

9,188

  Sales and marketing

10,293

10,589

  General and administrative

10,536

10,531

(2) Amortization of acquisition-related intangibles included in above line items:

  Cost of licensing

$          6,590

$          6,610

  Cost of products and services

768

753

  Sales and marketing

352

340

  General and administrative

1,554

1,872

  Other income, net

441

441

Diluted earnings per share:

Fiscal Quarter Ended

June 26,
2026

June 27,
2025

GAAP diluted earnings per share

$           0.30

$           0.48

Stock-based compensation

0.33

0.32

Amortization of acquisition-related intangibles

0.10

0.10

Restructuring charges/(credits)

0.04

(0.01)

Income tax adjustments

(0.08)

(0.11)

Non-GAAP diluted earnings per share

$           0.69

$           0.78

Weighted-average shares outstanding – diluted (in thousands)

94,518

96,900

The following tables present a reconciliation between GAAP and non-GAAP versions of the estimated financial measures for the fourth quarter of
fiscal 2026 and full year fiscal 2026 included in this release:

Gross margin:

Q4 2026

Fiscal 2026

GAAP gross margin

88.0 %

88.0 %

Stock-based compensation

0.1 %

0.1 %

Amortization of acquisition-related intangibles

1.9 %

1.9 %

Non-GAAP gross margin

90.0 %

90.0 %

Operating expenses (in millions):

Q4 2026

Fiscal 2026

GAAP operating expenses (low – high end of range)

$227 – $237

$937 – $947

Stock-based compensation

(30)

(127)

Amortization of acquisition-related intangibles

(2)

(8)

Restructuring charges

(17)

Non-GAAP operating expenses (low – high end of range)

$195 – $205

$785 – $795

Operating margin:

Fiscal 2026

GAAP operating margin

21% +/-

Stock-based compensation

9 %

Amortization of acquisition-related intangibles

3 %

Restructuring charges

1 %

Non-GAAP operating margin

34% +/-

Effective tax rate:

Q4 2026

Fiscal 2026

GAAP effective tax rate

23.0 %

24.0 %

Stock-based compensation (low – high end of range)

(2%) – 1%

(2%) – 0%

Amortization of acquisition-related intangibles (low – high end of
range)

(1%) – 0%

(1%) – 0%

Non-GAAP effective tax rate

21.0 %

21.0 %

Diluted earnings per share:

Q4 2026

Fiscal 2026

Low

High

Low

High

GAAP diluted earnings per share (low – high end of range)

$           0.78

$         0.93

$           2.62

$         2.77

Stock-based compensation  (low – high end of range)

0.32

0.32

1.33

1.33

Amortization of acquisition-related intangibles (low – high end of
range)

0.10

0.10

0.41

0.41

Restructuring charges (low – high end of range)

0.18

0.18

Income tax adjustments (low – high end of range)

(0.07)

(0.07)

(0.29)

(0.29)

Non-GAAP diluted earnings per share (low – high end of range)

$           1.13

$         1.28

$           4.25

$         4.40

Weighted-average shares outstanding – diluted (in thousands)

93,600

93,600

95,200

95,200

Investor Contact:
Peter Goldmacher
415-254-7415
peter.goldmacher@dolby.com

Media Contact:
media@dolby.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dolby-laboratories-reports-third-quarter-2026-financial-results-302839283.html

SOURCE Dolby Laboratories, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

ZIONS BANCORPORATION’S BOARD ANNOUNCES APPROVAL OF SHARE REPURCHASE AND DECLARES DIVIDENDS ON COMMON AND PREFERRED STOCK

Published

on

By

SALT LAKE CITY, July 30, 2026 /PRNewswire/ — Zions Bancorporation, N.A. (NASDAQ: ZION) announced today that its board of directors has authorized share repurchases of up to $75 million of the company’s common stock for the third quarter of 2026 as part of the company’s previously authorized share repurchase target for 2026 of $300 million. The timing and amounts of any such actions will depend on market conditions, regulatory requirements, and other factors or uncertainties and may be updated at the discretion of the board.

The board also declared a regular quarterly dividend of $0.48 per common share, payable August 20, 2026, to shareholders of record at the close of business on August 13, 2026. The dividend represents a $0.03, or 6.7%, increase from the prior quarter.

Additionally, the board declared the regular quarterly cash dividend on the company’s Series A perpetual preferred shares (NASDAQ: ZIONP; CUSIP: 98973A104). The cash dividends on the preferred shares are payable September 15, 2026, to shareholders of record on September 1, 2026.

Zions Bancorporation, N.A. is one of the nation’s premier financial services companies with approximately $89 billion of total assets at December 31, 2025, and annual net revenue of $3.4 billion in 2025. Zions operates under local management teams and distinct brands in 11 western states: Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming. The Bank is a consistent recipient of national and state-wide customer survey awards in small- and middle-market banking, as well as a leader in public finance advisory services and Small Business Administration lending. In addition, Zions is included in the S&P MidCap 400 and NASDAQ Financial 100 indices. Investor information and links to local banking brands can be accessed at www.zionsbancorporation.com.  

View original content to download multimedia:https://www.prnewswire.com/news-releases/zions-bancorporations-board-announces-approval-of-share-repurchase-and-declares-dividends-on-common-and-preferred-stock-302839563.html

SOURCE Zions Bancorporation

Continue Reading

Technology

Proteotype Unveils Alchemi®, the Data and Orchestration Platform Behind Enlighten®

Published

on

By

With approximately €499,000 from the EIC Pre-Accelerator, Alchemi® is being developed to connect laboratory measurements, multi-country clinical data and healthcare workflows, supporting secure, interoperable deployment across distributed laboratories.

TORRES VEDRAS, Portugal, July 30, 2026 /PRNewswire/ — Proteotype Diagnostics Unipessoal LDA (“Proteotype”) today unveiled Alchemi®, its proprietary data and clinical workflow platform being developed for Enlighten®, the company’s investigational blood-based multi-cancer test.

Enlighten® measures changes in the body’s response to tumour development using a laboratory kit. Alchemi® is designed to standardise those measurements, govern analytical and machine-learning workflows and generate traceable, clinician-facing outputs. By supporting interoperability across laboratory and health-record systems through standards including HL7 FHIR and SNOMED CT, Alchemi® is intended to reduce reliance on a single central testing facility and make Enlighten® easier to integrate into local care pathways.

Proteotype’s MODERNISED and INNOVATOR studies are expanding the clinical evidence supporting Enlighten®. Alchemi® is intended to provide shared digital infrastructure through which multi-country datasets can be securely governed, analysed and translated into future clinical workflows.

Alchemi® will combine secure harmonisation of pseudonymised data generated across countries and laboratory environments; controlled development and validation of explainable machine-learning models; regulatory-compliant traceability; and a multilingual clinician portal for test ordering, result viewing and workflow management.

Its models are being designed to provide interpretable outputs, uncertainty measures and traceability of the data, model version and processing steps used to generate each result. A modular architecture will support jurisdiction-appropriate cloud deployment, with encryption, controlled access and comprehensive audit trails.

The 15-month development programme begins on 1 September 2026 and is supported by approximately €499,000 from the European Innovation Council’s Pre-Accelerator. The grant will support machine-learning optimisation, multi-country data harmonisation, clinician-interface development, interoperability, cloud security, and medical-device and software lifecycle, quality and technical documentation.

Proteotype was among 70 deep-tech companies selected from 22 countries under the EIC Pre-Accelerator call, which awarded approximately €32.5 million in total funding.

Wesley Sukdao, CEO and Co-Founder of Proteotype Diagnostics, said:

“Until now, we have spoken mainly about the biology and clinical studies behind Enlighten®. Alchemi® reveals the other half of the product: the secure data and software infrastructure required to turn laboratory measurements into reliable clinician-facing results. As our evidence base grows across cancers, countries and care settings, Alchemi® will help us manage that complexity while keeping Enlighten® scalable and accessible”

Dr Emma Yates, Chief Scientific Officer and Co-Founder, said:

“A diagnostic platform must do more than apply a machine-learning model. It must preserve the quality and traceability of every dataset, account for differences between populations and laboratory environments, and make clear how outputs are generated. Alchemi® is being built to provide that controlled, explainable and reproducible foundation for Enlighten®.”

Professor Gonçalo Bernardes, Co-Founder and Chair of Proteotype’s Scientific Advisory Board, said:

“Enlighten® combines a distinctive biological signal with laboratory technology and machine learning. Alchemi® brings those elements together as an integrated system, creating the infrastructure needed to translate scientific discovery into a clinically deployable and scalable diagnostic platform.”

Development will be led from Proteotype’s Torres Vedras site, where the company is recruiting for full-time roles in software engineering, data engineering, cybersecurity and healthcare integration.

About Proteotype Diagnostics

Proteotype is a pioneering diagnostics company dedicated to the development of advanced multi-cancer early detection and personalised medicine tests that measure the host response to tumour development. Its lead product, Enlighten®, is being evaluated as an accessible and scalable multi-cancer test designed to support earlier investigation and better-informed clinical decision-making.

Media contact: pr@proteotype.com
Career opportunities: https://proteotype.com/careers
General enquiries: support@proteotype.com

Funded by the European Union.

View original content to download multimedia:https://www.prnewswire.com/news-releases/proteotype-unveils-alchemi-the-data-and-orchestration-platform-behind-enlighten-302839577.html

SOURCE Proteotype Diagnostics

Continue Reading

Technology

FUJIFILM GFX100RF: A 102 MP Point-and-Shoot Medium Format Camera; YouTube Video at B&H

Published

on

By

FUJIFILM GFX100RF features a 102MP medium format sensor to a compact, all-in-one camera design for the ultimate everyday camera for photographers.

NEW YORK, July 30, 2026 /PRNewswire/ — B&H is pleased to share the medium format camera built to fit in a to-go bag, the compact, rangefinder-inspired GFX100RF packs all the quality and performance of its 102MP sensor and X Processor 5 into a sleek, lightweight, all-metal housing.

Coming in silver and black finishes, the camera features a built-in fixed focal length FUJINON GF 35mm f/4 lens and offers photographers an array of creative options, including the innovative Aspect Ratio Dial, 20 FUJIFILM film simulations, digital tele-conversion at three different focal lengths, and an Internal ND filter. While capable of 4K30p internal and external recording, this camera was designed for photographers seeking an uncompromising tool for their all-day, everyday creative practice.

FUJIFILM GFX100RF Digital Camera (silver) 
https://www.bhphotovideo.com/c/product/1884991-REG/fujifilm_16938065_gfx100_rangefinder_camera.html

FUJIFILM GFX100RF Digital Camera (black) 
https://www.bhphotovideo.com/c/product/1884990-REG/fujifilm_16938039_gfx100_rangefinder_camera.html 

Key Features

Smallest, Lightest GFX + Built-In Lens102MP 43.8 x 32.9mm BSI CMOS II SensorFUJINON GF 35mm f/4 Lens (28mm Equiv.)Aspect Ratio Dial, Digital TeleconverterInternal 4-Stop ND Filter + Leaf Shutter5.76m-Dot OLED EVF3.2″ 2.1m-Dot 3-Way Tilting TouchscreenDCI 4K30p + External ProRes Recording20 Film Simulation Modes & Q MenuIncluded Lens Hood and Filter Adapter

The heart of GFX100RF camera is its massive 43.8 x 32.9mm, 102MP CMOS sensor, with a native ISO 80 sensitivity and a whopping 70% more light-gathering area than a full-frame camera. It’s the same sensor in its bigger GFX siblings, and unlocks the same expanded low-light capabilities, image detail, accurate 16-bit color, dynamic range, and low depth-of-field effects. The sensor is paired with FUJIFILM’s fastest X-Processor 5 to optimize the camera’s performance and functionality.

See our YouTube Video  https://www.youtube.com/watch?v=qjQR0ZeeEYE

About B&H Photo Video

As the world’s largest source of photography, video, and audio equipment, as well as computers, drones, and home and portable entertainment, B&H is known worldwide for its attentive, knowledgeable sales force and excellent customer service, including fast, reliable shipping. B&H has been satisfying customers worldwide for over 50 years.

Visitors to the website can access a variety of educational videos and enlightening articles. The B&H YouTube Channel has an unmatched wealth of educational content. Our entertaining and informative videos feature product overviews from our in-house specialists. You can view the B&H Event Space presentations from many of the world’s foremost experts and interviews with some of technology’s most dynamic personalities. Tap into this exciting resource by subscribing to the B&H YouTube Channel here. In addition to videos, the B&H Explora blog presents new product announcements, gear reviews, helpful guides, and tech news written by product experts and industry professionals, as well as our award-winning podcasts.

When you’re in Manhattan, take a tour of the B&H Photo SuperStore, located at 420 Ninth Avenue. The techno-carousel spins all year round at the counters and kiosks at B&H. With hundreds of products on display, the B&H Photo SuperStore is the place to test-drive and compare all the latest gear.

The B&H Payboo Credit Card offers the industry’s best instant savings and special financing, subject to credit approval. Visit B&H’s Payboo Page to learn more and apply.

Contact Information
Geoffrey Ngai

B&H Photo Video
212-615-8820
https://www.bhphotovideo.com/ 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fujifilm-gfx100rf-a-102-mp-point-and-shoot-medium-format-camera-youtube-video-at-bh-302839520.html

SOURCE B&H Photo

Continue Reading

Trending